High affinity immunoglobulin epsilon receptor (FcεRI) bound to Festuca pratensis-specific IgE (FcεRI-IgE (Festuca pratensis))

This target represents the molecular complex formed when Immunoglobulin E (IgE) antibodies, specifically those recognizing allergens from Festuca pratensis (Meadow fescue) pollen, are bound to the high-affinity IgE receptor (FcεRI) on the surface of mast cells and basophils (Source: UniProt P12319; WHO/IUIS Allergen Nomenclature). Festuca pratensis is a common forage grass whose pollen contains potent allergens such as Fes p 1 and Fes p 5, which are major triggers for seasonal allergic rhinitis and asthma in sensitized individuals (Source: PubMed PMID: 11749634). When these allergens encounter the IgE-FcεRI complex, they cross-link the receptors, triggering a signaling cascade that leads to the release of inflammatory mediators like histamine, leukotrienes, and cytokines (Source: StatPearls, Type I Hypersensitivity). This process is the hallmark of Type I hypersensitivity reactions. Therapeutic strategies targeting this complex include monoclonal antibodies like Omalizumab, which sequesters free IgE to prevent its binding to FcεRI, and allergen-specific immunotherapy (AIT), which aims to induce immune tolerance and shift the antibody response from IgE to protective IgG4 (Source: FDA Omalizumab Label; PubMed PMID: 30243446).

Other names

Meadow fescue-specific IgE-FcεRI complexFes p-specific IgE-receptor complexIgE-FcεRI complexFestuca pratensis pollen allergen-IgE-FcεRI complex

Anti-IgE monoclonal antibodies bind to the Cε3 domain of free IgE, preventing its interaction with the alpha subunit of FcεRI on mast cells and basophils. Allergen-specific immunotherapy involves the controlled administration of Festuca pratensis extracts to induce immune tolerance, characterized by a shift from a Th2 to a Th1 response and the production of allergen-specific IgG4 blocking antibodies.